YBX1 and breast carcinoma: Other studies describe that in HER2‐amplified breast cancer, YB‐1 inhibition by targeting RSK repressed resistance to trastuzumab or that resistance to taxane in PCa therapy is linked to RSK and to its downstream target YB‐1 (Astanehe et al., 2012) (Shiota et al., 2014).